Linsitinib

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Linsitinib (ASP-7487, OSI-906) is a potent, selective, orally active, dual IGF-1R/insulin receptor inhibitor with IC50 of 35/75 nM, respectively.

Linsitinib (ASP-7487, OSI-906) is a potent, selective, orally active, dual IGF-1R/insulin receptor inhibitor with IC50 of 35/75 nM, respectively; potently and selectively inhibits autophosphorylation of both human IGF-1R and IR, displays in vitro antiproliferative effects in a variety of tumor cell lines and shows robust in vivo anti-tumor efficacy in an IGF-1R-driven xenograft model.Liver Cancer Phase 3 Clinical

ASP-7487;ASP 7487;OSI-906;OSI906

Angiogenesis

IGF-1R

IGF-1R;InsulinReceptor;IRR

Cancer

Liver Cancer

867160-71-2

421.49

C26H23N5O

>98% (HPLC)

10 mM in DMSO

O[C@@]1(C)C[C@H](C2=NC(C3=CC=C4C=CC(C5=CC=CC=C5)=NC4=C3)=C6C(N)=NC=CN62)C1

Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-, cis-

(-20℃)

With Ice Pack

≥ 2 years